Generic For Antiretroviral Viread Gets FDA Tentative Approval
Featured ArticleMain Category: HIV / AIDS
Also Included In: Regulatory Affairs / Drug Approvals; Pharma Industry / Biotech Industry
Article Date: 19 Dec 2007 - 0:00 PDT
| Patient / Public: | ![]() |
3 (1 votes) |
| Healthcare Prof: | ![]() |
As part of the President's Emergency Plan for AIDS Relief, the FDA (Food and Drug Administration) has granted a tentative approval for a generic version of antiretroviral tenofovir disoproxil fumarate (Viread). Tenofovir disoproxil fumarate is used as a combination treatment of HIV - it is used along with other antiretroviral agents.
What is Tentative Approval?
It means that although the drug still enjoys existing patents and/or marketing exclusivity, it meets all the FDA's manufacturing quality and clinical safety and efficacy requirements. In this case, it is the first tentative approval for an nRTI (nucleotide analog reverse transcriptase inhibitor) - a drug that blocks transcriptase, an enzyme which is vital for HIV production.
Gary Buehler, Director, Office of Generic Drugs, FDA, says "The fight to save lives with high-quality anti-retroviral treatment is of significant importance to FDA. Our scientists have been working diligently to make safe and effective treatments for AIDS available as quickly as possible to combat this worldwide problem."
PEPFAR (the President's Emergency Plan for AIDS Relief) is a 5-year $15 billion endeavor to combat HIV/AIDS globally - it is the largest single commitment to fighting global HIV/AIDS. Tenofovir disoproxil fumarate is the latest addition of an anti-retroviral product to this effort.
All FDA reviews of applications which are linked to PEPFAR are dealt with swiftly. This case, of generic tenofovir disoproxil fumarate tablets, took under six months to review.
The tenofovir disoproxil fumarate 300 milligram tablets are produced by Matrix Laboratories, LTD, Andhra Pradesh, India.
www.pepfar.gov
www.fda.gov/oia/pepfar.htm
Written by - Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/articles/92204.php>
APA
http://www.medicalnewstoday.com/articles/92204.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




